Abbott Laboratories Overview
Pro stress-test →Abbott is a global healthcare leader with a portfolio of life-changing technologies spanning diagnostics, medical devices, nutritionals and branded generic medicines. The company has 115,000 colleagues serving people in more than 160 countries. Abbott has successfully transitioned from pandemic-era COVID-19 testing revenues to a diversified growth platform anchored in metabolic health biowearables and structural heart technologies.
Strategic Profile
Pro stress-test →The company has shifted from COVID-19 testing toward a future anchored in metabolic health and consumer-facing biowearables, solidifying its position as a defensive growth stock. The FreeStyle Libre platform is Abbott's crown jewel—the Libre 3 is the world's most widely used Continuous Glucose Monitor, on track to reach $10 billion in annual revenue by 2028. Abbott announced an agreement to acquire Exact Sciences, positioning the company to enter and lead in the fast-growing cancer diagnostics market, with transaction expected to close in Q2 2026.
Competitive Landscape
Pro stress-test →In nutrition, Abbott competes against Nestlé and Danone, relying on its clinical heritage to maintain doctor-recommended status. In diabetes and cardiovascular devices, Abbott faces competition from traditional medical device manufacturers, while its Lingo biowearable competes with consumer health tech companies. GLP-1 manufacturers like Novo Nordisk and Eli Lilly were initially feared as threats, but data now shows synergistic usage with Abbott's CGM platforms.
Industry Context
Abbott Laboratories operates in Diversified Healthcare (Medical Devices, Diagnostics, Pharmaceuticals, Nutrition).
Key facts
Founded: 1888 · Headquarters: Abbott Park, Illinois, United States · Employees: 115000 · Revenue: $46.5B · Market cap: $200B